Sermorelin
GHRH Analog (1-29)
- Form
- Lyophilized powder
- Storage
- -20°C (lyophilized)
- Origin
- USA lab
from$79
Sermorelin is a synthetic growth-hormone-releasing-hormone analog (GRF 1-29) reference material used in laboratory investigations of GHRH-receptor activity and associated signaling pathways.
- GHRH-receptor signaling research
- Secretagogue-pathway studies
- In-vitro receptor-response models
SKU: AP-SERMORELIN-5MG
3 vial minimum per order — mix any products
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reconstitution ReferenceOptional — how strong is the mixed vial?
Mixing a powder vial with water? Fill in the fields — results update as you type.
Mixing 5 mg of peptide into 2 mL of water makes a 2.5 mg/mL solution. Each 0.1 mL contains 0.25 mg.
Reference for in-vitro laboratory handling only. Outputs describe the physical properties of the reconstituted vial (concentration and mass drawn) — they are not dosing guidance, administration instructions, or medical advice. Verify all measurements independently.
The science behind Sermorelin
A structured overview of the published literature surrounding Sermorelin as a GHRH-analog research peptide.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29), the shortest fully active fragment. It is studied as a reference material for GHRH-receptor signaling research.
The peptide is a well-established tool in neuroendocrine pharmacology for probing the GHRH-receptor axis.
The material supplied here is a laboratory reference standard, and the summaries below describe only findings reported in published research.
Sermorelin was developed from research showing that the N-terminal 1-29 fragment of GHRH retains full biological activity, providing a defined research peptide for GHRH-axis studies.
The literature includes preclinical and clinical neuroendocrine research examining GHRH-receptor signaling and growth-hormone regulation.
The primary mechanism studied is agonism at the GHRH receptor, a class-B GPCR, reported to stimulate cAMP-dependent growth-hormone release from pituitary-cell models.
Researchers study GHRH-axis feedback dynamics using sermorelin as a reference agonist in preclinical systems.
GHRH-receptor assays
Used as a reference agonist in GHRH-receptor activation studies.
Secretagogue signaling
Examined in pituitary growth-hormone-release models.
Neuroendocrine research
Studied in preclinical GHRH-axis systems.
Comparative pharmacology
Referenced alongside other GHRH analogs.
What is Sermorelin?
A synthetic GHRH-analog peptide (GRF 1-29) supplied as a laboratory reference material for GHRH-receptor signaling research.
What kind of research references Sermorelin?
Neuroendocrine pharmacology studies of GHRH-receptor activation and growth-hormone regulation.
Is Sermorelin approved for human or veterinary use?
No. Sermorelin is not approved by the FDA or any regulatory authority for human or animal use. It is sold exclusively for in-vitro and laboratory research and is not for consumption.
How is the reference material characterized?
Each released lot is supplied as a lyophilized powder with a lot-specific certificate of analysis reporting HPLC purity of ≥ 99%. The certificate is tied to the specific released lot.
How should the compound be stored?
Lyophilized material is typically stored at -20°C, protected from light and moisture. Handling should follow standard laboratory practice for peptide reference materials. We do not provide reconstitution, dosing, or administration guidance.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999).
- GHRH(1-29) structure-activity literature (review).
Links open a curated peer-reviewed search on PubMed. Allpointe Bio Research is not affiliated with the cited authors or publishers.
Research-Use Statement
The information above is provided for educational and scientific-reference purposes only and summarizes findings reported in the published preclinical and in-vitro literature. It is not medical advice and does not describe outcomes, benefits, or applications for humans or animals. Sermorelin is supplied strictly as a laboratory reference material for in-vitro and research use only — it is not a drug or supplement, is not approved for human or veterinary use, and is not for consumption. Allpointe Bio Research does not provide clinical, dosing, reconstitution, or administration guidance.